Development of the drug oncolytic immunotherapy based on vaccinia viruses (Vaccinia virus, Orthopoxvirus, Chordopoxvirinae, Poxviridae) against breast cancer
- Authors: Bauer T.V.1, Tregubchak T.V.1, Maksyutov A.Z.1, Maksyutov R.A.1, Kolosova I.V.1, Gavrilova E.V.1
-
Affiliations:
- State Research Center of Virology and Biotechnology «Vector»
- Issue: Vol 65, No 1 (2020)
- Pages: 49-56
- Section: ORIGINAL RESEARCH
- URL: https://journals.rcsi.science/0507-4088/article/view/118050
- DOI: https://doi.org/10.36233/0507-4088-2020-65-1-49-56
- ID: 118050
Cite item
Full Text
Abstract
Introduction. Currently, new directions in cancer therapy are actively developing, one of which is oncolytic immunotherapy. This approach would be to use of viruses as cancer specific cytolytic agents capable of stimulating both the tumor-specific and non-specific immune response.
The objective paper was obtain a recombinant vaccinia virus containing genes encoding immunostimulating molecules and study oncolytic and immunostimulating properties of recombinant virus.
Material and methods. MTT test, ELISA, methods of transient dominant selection.
Results. The recombinant vaccinia virus (L-IVP_oncoB) were obtained with deletion of the gene encoding thymidine kinase and had an integrated gene encoding GM-CSF. Also the virus have deletion of the gene encoding viral growth factor and integrated genes encoding synthetic tumor-specific polyepitopic immunogens. It was shown that the modifications made to the viral genome did not affect the growth characteristics of the virus when cultured on CV-1 and 4647 cell cultures, and the cytopathogenic efficacy of the virus was determined in relation to cancer cultures of cells of various genesis. In in vivo experiment, it was revealed that the polyepitopic construct in the genome L-IVP_oncoB is able to initiate a change in the profile of cytokines.
Discussion. The obtained data characterized L-IVP_oncoB as a promising cytopathogenic and immunostimulating agent and showed the need for further study of its properties as means of oncolytic immunotherapy. Conclusion. The basic experiments on the evaluation of the biological properties of the obtained L-IVP_oncoB, which are necessary for the characterization of the oncolytic virus, have been carried out.
Full Text
##article.viewOnOriginalSite##About the authors
T. V. Bauer
State Research Center of Virology and Biotechnology «Vector»
Author for correspondence.
Email: bauer_tv@vector.nsc.ru
ORCID iD: 0000-0002-4954-9905
Tatyana V. Bauer, PhD student, Junior Research Scientistof the department of genomic research.
Koltsovo, Novosibirsk Region, 630559
Russian FederationT. V. Tregubchak
State Research Center of Virology and Biotechnology «Vector»
Email: fake@neicon.ru
ORCID iD: 0000-0001-9608-2044
Koltsovo, Novosibirsk Region, 630559 Russian Federation
A. Z. Maksyutov
State Research Center of Virology and Biotechnology «Vector»
Email: fake@neicon.ru
ORCID iD: 0000-0002-4027-8299
Koltsovo, Novosibirsk Region, 630559 Russian Federation
R. A. Maksyutov
State Research Center of Virology and Biotechnology «Vector»
Email: fake@neicon.ru
ORCID iD: 0000-0003-2317-4153
Koltsovo, Novosibirsk Region, 630559 Russian Federation
I. V. Kolosova
State Research Center of Virology and Biotechnology «Vector»
Email: fake@neicon.ru
ORCID iD: 0000-0003-1314-281X
Koltsovo, Novosibirsk Region, 630559 Russian Federation
E. V. Gavrilova
State Research Center of Virology and Biotechnology «Vector»
Email: fake@neicon.ru
ORCID iD: 0000-0002-7118-5749
Koltsovo, Novosibirsk Region, 630559 Russian Federation
References
- Youlden D.R., Cramb S.M., Dunn N.A., Muller J.M., Pyke C.M., Baade P.D. The descriptive epidemiology of female breast cancer: an international comparison of screening, incidence, survival and mortality. Cancer Epidemiol. 2012; 36(3): 237-48. https://doi.org/10.1016/j.canep.2012.02.007
- Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2017. CA Cancer J. Clin. 2017; 67(1): 7-30. https://doi.org/10.3322/caac.21387
- Rouzier R., Perou C.M., Symmans W.F., Ibrahim N., Cristofanilli M., Anderson K., et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin. Cancer Res. 2005; 11(16): 5678-85. https://doi.org/10.1158/1078-0432.CCR-04-2421
- Nixon N.A., Hannouf M.B., Verma S. A review of the value of human epidermal growth factor receptor 2 (HER2)-targeted therapies in breast cancer. Euro. J. Cancer. 2018; 89: 72-81. https://doi.org/10.1016/j.ejca.2017.10.037
- Fong P.C., Boss D.S., Yap T.A., Tutt A., Wu P., Mergui-Roelvink M., et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 2009; 361(2): 123-34. https://doi.org/10.1056/NEJMoa0900212
- Butti R., Gunasekaran V.P., Kumar T.V.S., Banerjee P., Kundu G.C. Breast cancer stem cells: Biology and therapeutic implications. Int. J. Biochem. Cell. Biol. 2019; 107: 38-52. https://doi.org/10.1016/j.biocel.2018
- Delgado-Bellido D., Serrano-Saenz S., Fernández-Cortés M., Oliver F.J. Vasculogenic mimicry signaling revisited: focus on nonvascular VE-cadherin. Mol. Cancer. 2017; 16(1): 65. https://doi.org/10.1186/s12943-017-0631-x
- Economopoulou P., Kaklamani V.G., Siziopikou K. The role of Cancer stem cells in breast Cancer initiation and progression: potential Cancer stem cell-directed therapies. Oncologist. 2012; 17(11): 1394-401. https://doi.org/10.1634/theoncologist.2012-0163
- Garber K. China approves world’s first oncolytic. J. Natl. Cancer Inst. 2006; 98(5): 298-300. https://doi.org/10.1093/jnci/djj111
- Jaunalksne I., Brokāne L., Petroška D., Rasa A., Alberts P. ECHO-7 oncolytic virus Rigvir® in an adjuvant setting for stage I uveal melanoma; A retrospective case report. Am. J. Ophthalmol. Case Rep. 2020; 17: 100615. http://doi.org/10.1016/j.ajoc.2020.100615
- Adam J., Robertson J., Donegan E., Voicechovskaja I. NICE guidance for talimogene laherparepvec for unresectable metastatic melanoma. Lancet Oncol. 2016; 17(11): 1485-6. https://doi.org/10.1016/S1470-2045(16)30489-2
- Falkner F.G., Moss B. Transient dominant selection of recombinant vaccinia viruses. J. Virol. 1990; 64(6): 3108-11.
- Cheever M.A., Allison J.P., Ferris A.S., Finn O.J., Hastings B.M., Hecht T.T., et al. The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research. Clin. Cancer Res. 2009; 15(17): 5323-37. https://doi.org/10.1158/1078-0432.CCR-09-0737
- Schlom J. Therapeutic Cancer Vaccines: Current Status and Moving Forward. J. Natl. Cancer Inst. 2012; 104(8): 599-613. https://doi.org/10.1093/jnci/djs033
- Milani A., Sangiolo D., Aglietta M., Valabrega G. Recent advances in the development of breast cancer vaccines. Breast Cancer (Dove Med. Press). 2014; 6: 159-68. https://doi.org/10.2147/BCTT.S38428
- Thomson S.A., Khanna R., Gardner J., Burrows S.R., Coupar B., Moss D.J., et al. Minimal epitopes expressed in a recombinant polyepitope protein are processed and presented to CD8+ cytotoxic T cells: implications for vaccine design. Proc. Natl. Acad. Sci. USA. 1995; 92(13): 5845-9. https://doi.org/10.1073/pnas.92.13.5845
- Eslami N.S., Shokrgozar M.A., Mousavi A., Azadmanesh K., Nomani A., Apostolopoulos V., et al. Simultaneous immunisation with a Wilms’ tumour 1 epitope and its ubiquitin fusions results in enhanced cell mediated immunity and tumour rejection in C57BL/6 mice. Mol. Immunol. 2012; 51(3-4): 325-31. https://doi.org/10.1016/j.molimm.2012.03.033
- Seyed N., Taheri T., Vauchy C., Dosset M., Godet Y., Eslamifar A., et al. Immunogenicity Evaluation of a Rationally Designed Polytope Construct Encoding HLA-A*0201 Restricted Epitopes Derived from Leishmania major Related Proteins in HLA-A2/DR1 Transgenic Mice: Steps toward Polytope Vaccine. PLoS One. 2014; 9(10): e108848. https://doi.org/10.1371/journal.pone.0108848
- Nemec A.A., Wallace S.S., Sweasy J.B. Variant base excision repair proteins: Contributors to genomic instability. Semin. Cancer Biol. 2010; 20(5): 320-8. https://doi.org/10.1016/j.semcancer.2010.10.010
- Horii R., Akiyama F., Kasumi F., Koike M., Sakamoto G. Spontaneous healing of breast cancer. Breast Cancer. 2005; 12(2): 140-4. https://doi.org/10.2325/jbcs.12.140
- Allegrezza M.J., Conejo-Garcia J.R. Targeted Therapy and Immunosuppression in the Tumor Microenvironment. Trends Cancer. 2017; 3(1): 19-27. https://doi.org/10.1016/j.trecan.2016.11.009
- Peres L.P., da Luz F.A., Pultz B.A., Brígido P.C., de Araújo R.A., Goulart L.R. Peptide vaccines in breast cancer: The immunological basis for clinical response. Biotechnol. Adv. 2015; 33(8): 1868-77. https://doi.org/10.1016/j.biotechadv.2015.10.013
- Borsig L., Wolf M.J., Roblek M., Lorentzen A., Heikenwalder M. Inflammatory chemokines and metastasis — tracing the accessory. Oncogene. 2013; 33(25): 3217-24. https://doi.org/10.1038/onc.2013.272
- Salazar-Onfray F., López M.N., Mendoza-Naranjo A. Paradoxical effects of cytokines in tumor immune surveillance and tumor immune escape. Cytokine Growth Factor Rev. 2007; 18(1-2): 171-82. https://doi.org/10.1016/j.cytogfr.2007.01.015
- Chen Q., Daniel V., Maher D.W., Hersey P. Production of IL-10 by melanoma cells: examination of its role in immunosuppression mediated by melanoma. Int. J. Cancer. 1994; 56(5): 755-60. https://doi.org/10.1002/ijc.2910560524
- Giovarelli M., Musiani P., Modesti A., Dellabona P., Casorati G., Allione A., et al. Local release of IL-10 by transfected mouse mammary adenocarcinoma cells does not suppress but enhances antitumor reaction and elicits a strong cytotoxic lymphocyte and antibody-dependent immune memory. J. Immunol. 1995; 155(6): 3112-23.
- Chen W., Zlotnik A. IL-10: a novel cytotoxic T cell differentiation factor. J. Immunol. 1991; 147(2): 528-34.
- Kaufman H.L., Rao J.B., Irivine K.R., Bronte V., Rosenberg S.A., Restifo N.P. Interleukin-10 enhances the therapeutic effectiveness of a recombinant poxvirus-based vaccine in an experimental murine tumor model. J. Immunother. 1999; 22(6): 489-96. https://doi.org/10.1097/00002371-199911000-00003